Oramed CEO Nadav Kidron on CNBC: Oral insulin to be a gamechanger

Oral insulin to be a game changer: Oramed CEO Nadav Kidron tells CNBC
On Squawk Box Asia, Kidron talks about the company’s latest offering
 

Categories: In the News|

BioTuesdays: Oramed hopes to start Phase 3 oral insulin trial next year

Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what’s next for Oramed:

Oramed hopes to start Phase 3 oral insulin trial next year

Categories: In the News|

SEEKING ALPHA: Oramed Is Now The First To Show Evidence That Insulin Can Be Taken Orally

Injectable insulin has been around since 1923, but oral insulin has proven elusive to date.

Oramed Pharmaceuticals’ successful Phase IIB trial for oral insulin has shown that it can be done.

http://seekingalpha.com/article/3987206-oramed-now-first-show-evidence-insulin-can-taken-orally

 

Categories: In the News|

I24 News : Israeli Drugmaker Oramed Successfully Tests Insulin Pill

http://www.i24news.tv/en/tv/replay/evening-news/x4jqi3z 

 

Categories: In the News, Uncategorized|

Biopharma Dive: Oramed’s oral insulin shines in mid-stage trials

Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race…

http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/

 

Categories: In the News|

Market Exclusive: Weekly Biotech Report Part II, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)

Categories: In the News|

Reuters: Oramed Says Oral Insulin Succeeds in Midstage Type 2 Diabetes Trial

http://www.reuters.com/article/us-oramed-insulin-idUSKCN0Y91F2

Categories: In the News|

Be Forum: Dancing With Dragons, How a Small Israeli Company Struck a Historic Deal with a Chinese Giant

Josh Hexter, Oramed’s COO, spoke with Be Forum and about the company’s recent China deal.

www.beforum.org/the-bulletin/dancing-with-dragons

Categories: In the News|

BioTuesdays: Oramed sees value creating events through 2016

Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about Oramed’s progress and future advances.

“Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying […]

Categories: In the News|

Seeking Alpha: $50 Million Plus Royalties Deal Indicates Bright Future For Oramed’s Oral Insulin

seekingalpha.com/article/3723676-50-million-plus-royalties-deal-indicates-bright-future-for-orameds-oral-insulin?app=1&auth_param=k8111%3A1b5r8j9%3A005181aa590ef2f22df1979bdbb995c2&uprof=78

Categories: In the News|